It might be the latest version of a long-term strategic policy approach, but stakeholders need to ask themselves a critical question. Are they willing to trade a bridging fund and process changes for a few health technologies, based on the promise it could accelerate access, in return for a disinvestment framework and deprioritising most new therapies?
Stakeholders deserve clarity on the strategic objective before this process gets underway
November 25, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
Your success makes you a target and take it as a compliment
September 16, 2026 - -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News
